UK company Shire Pharmaceuticals has signed agreements with Synaptec and MacFarlan Smith regarding galanthamine, an acetylcholinesterase inhibitor which may be of use in the treatment of dementia. The deal gives Shire worldwide rights to the agent outside North American Free Tade Association countries, Japan and four Far Eastern markets. The company hopes to begin Phase III testing next year.
Shire notes that MacFarlan Smith has developed a method of extracting galanthamine from natural sources, and Shire now owns intellectual rights to this technology and will sell the raw material globally. The company says it is also investigating, in collaboration with fellow UK firm Chiroscience, the possibility of developing a synthetic manufacturing process for this chiral compound.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze